scholarly journals Sexual dysfunction associated with prostate cancer treatment in Japanese men: a qualitative research

Author(s):  
Saeko Hayashi ◽  
Fumiko Oishi ◽  
Kazuki Sato ◽  
Hiromi Fukuda ◽  
Shoko Ando

Abstract Purpose We investigated the experiences of Japanese men with sexual dysfunction associated with various prostate cancer treatments. Methods We included 38 Japanese men who underwent the following initial treatments for prostate cancer: radical prostatectomy (n = 10), external beam radiotherapy (n = 12), brachytherapy (n = 5), and androgen deprivation therapy (n = 11). Semi-structured interviews were conducted regarding sexual dysfunction associated with prostate cancer treatment. Data were analyzed using a content analysis method. To obtain a unique experience for each treatment, we confirmed and organized the treatment method from which the code that constituted each category was derived. The category reliability was calculated based on Scott’s formula for the matching rate of the classification by three qualitative researchers. The criterion for good reliability was set at 70%. Results Japanese men with sexual dysfunction associated with prostate cancer treatments experienced the following: a desire to maintain sexual function and conflict in decision-making concerning the initial treatment for prostate cancer; a loss of values related to sexual dysfunction; an uncertainty regarding the consequences of sexual dysfunction; a sense of calm with fewer adverse effects of sexual dysfunction at the early treatment stage; an effort to accept sexual dysfunction; and management of their changed body at the later treatment stages. The concordance rates for the categories were 70% and 78%. Additionally, there were glimpses of experiences common to all treatments and trends in treatment-specific experiences. Conclusion It is necessary to provide care based on the experience of Japanese men with sexual dysfunction after prostate cancer treatment.

2019 ◽  
Vol 17 (6) ◽  
pp. 527-537 ◽  
Author(s):  
Salma A M El Badri ◽  
Abdulazeez Salawu ◽  
Janet E Brown

Abstract Purpose of Review The improvement in prostate cancer survival over time, even in those with advanced disease, has led to an increasing recognition of the impact of prostate cancer and its treatment on bone health. Cancer treatment–induced bone loss (CTIBL) is a well-recognized entity but greater awareness of the risks associated with CTIBL and its treatment is required. Recent Findings The principal culprit in causing CTIBL is hormonal ablation induced by prostate cancer treatment, including several new agents which have been developed in recent years which significantly improve survival, but may cause CTIBL. This review discusses the impact of prostate cancer and its treatment on bone health, including published evidence on the underlying pathophysiology, assessment of bone health, and strategies for prevention and treatment. Summary It is important to recognize the potential cumulative impact of systemic prostate cancer treatments on bone health.


BMC Urology ◽  
2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Jeffrey A. Albaugh ◽  
Nat Sufrin ◽  
Brittany R. Lapin ◽  
Jacqueline Petkewicz ◽  
Sandi Tenfelde

2016 ◽  
Vol 39 (3) ◽  
pp. 276-279 ◽  
Author(s):  
Tammy Z. Movsas ◽  
Raphael Yechieli ◽  
Benjamin Movsas ◽  
May Darwish-Yassine

Author(s):  
Annemarijke van Luijtelaar ◽  
Jurgen J Fütterer ◽  
Joyce GR Bomers

Whole gland prostate cancer treatment, i.e. radical prostatectomy or radiation therapy, is highly effective but also comes with a significant impact on quality of life and possible overtreatment in males with low to intermediate risk disease. Minimal-invasive treatment strategies are emerging techniques. Different sources of energy are used to aim for targeted treatment in order to reduce treatment-related complications and morbidity. Imaging plays an important role in targeting and monitoring of treatment approaches preserving parts of the prostatic tissue. Multiparametric magnetic resonance imaging (mpMRI) is widely used during image-guided interventions due to the multiplanar and real-time anatomical imaging while providing an improved treatment accuracy. This review evaluates the available image-guided prostate cancer treatment options using MRI or magnetic resonance imaging/transrectal ultrasound (MRI/TRUS)-fusion guided imaging. The discussed minimal invasive image-guided prostate interventions may be considered as safe and feasible partial gland ablation in patients with (recurrent) prostate cancer. However, most studies focusing on minimally invasive prostate cancer treatments only report early stages of research and subsequent high-level evidence is still needed. Ensuring a safe and appropriate utilization in patients that will benefit the most, and applied by physicians with relevant training, has become the main challenge in minimally invasive prostate cancer treatments.


Urology ◽  
2016 ◽  
Vol 90 ◽  
pp. 19-26 ◽  
Author(s):  
Esmée M. Krouwel ◽  
Lorena A. Grondhuis Palacios ◽  
Hein Putter ◽  
Rob C.M. Pelger ◽  
Gert Jan Kloens ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document